

Supplemental Table 1: Multivariable analysis of outcomes after accelerated compared to standard infliximab induction for acute severe ulcerative colitis, stratified by study site

<u>Colectomy time point</u>	<u>Odds Ratio</u>	<u>95% confidence interval</u>
<u>Study site: Massachusetts General Hospital</u>		
<u>In-hospital</u>	<u>3.30</u>	<u>0.37 – 29.35</u>
<u>3 months</u>	<u>2.27</u>	<u>0.71 – 7.23</u>
<u>6 months</u>	<u>2.35</u>	<u>0.78 – 7.10</u>
<u>12 months</u>	<u>1.84</u>	<u>0.69 – 4.93</u>
<u>24 months</u>	<u>1.74</u>	<u>0.67 – 4.53</u>
<u>Study site: Indiana University</u>		
<u>In-hospital</u>	<u>N/A†</u>	
<u>3 months</u>	<u>N/A†</u>	
<u>6 months</u>	<u>1.00</u>	<u>0.18 – 5.52</u>
<u>12 months</u>	<u>0.45</u>	<u>0.08 – 2.61</u>
<u>24 months</u>	<u>0.36</u>	<u>0.06 – 1.97</u>
<u>Study site: Johns Hopkins Hospital</u>		
<u>In-hospital</u>	<u>0.37</u>	<u>0.03 – 4.09</u>
<u>3 months</u>	<u>0.45</u>	<u>0.07 – 2.73</u>
<u>6 months</u>	<u>0.35</u>	<u>0.06 – 2.13</u>
<u>12 months</u>	<u>0.27</u>	<u>0.05 – 1.63</u>
<u>24 months</u>	<u>0.28</u>	<u>0.05 – 1.71</u>

† - Odds ratios could not be calculated as there was no colectomy in the accelerated infliximab group in-hospital or at 3 months at this site.

Supplemental Table 2: Multivariable comparison of outcomes of up front dosing of 10mg/kg infliximab to standard induction therapy for acute severe ulcerative colitis

Colectomy time point	Odds Ratio	95% confidence interval	p-value
In-hospital	0.54	0.09 – 3.09	0.49
3 months	1.02	0.34 – 3.05	0.97
6 months	0.88	0.33 – 2.32	0.80
12 months	0.54	0.21 – 1.37	0.20
24 months	0.44	0.18 – 1.12	0.08